Transgenic antithrombin III Genzyme

IDrugs

Volumn 3, Issue 6, 2000, Pages 669-673

  Yeung, Pollen K F ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747610738     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Genzyme to spin off transgenics unit. SCRIP 1993 1830 11
2. Genzymes's product progress. SCRIP 1995 2037 17
3. Hambrecht & Quist Health Care Conference - San Francisco January 1996. HAMBRECHT & QUIST 1996 January 7-10
4. Genzyme ready for first transgenic protein trial. BIOWORLD WEEK 1996 4 15 3
5. Genzyme Transgenics' antithrombin III programme. SCRIP 1996 2122 13
6. Genzyme Transgenics begins first clinical trial of transgenic therapeutic product Genzyme Transgenics PRESS RELEASE 1996 September 5
7. First transgenic drug enters trials. SCRIP 1996 2164 24-25
8. Genzyme Transgenics' AT-III safe in clinical trial. Genzyme Transgenics Corp PRESS RELEASE 1996 October 21
9. Transgenics on trial. Carver Andrew SCRIP MAGAZINE 1996 Nov 51-53
10. Clinical trials update. SCRIP 1996 2181 23
11. Non-US clinical trials, regulatory submissions, recommendation and approvals: September 1996. BIOWORLD FINANCIAL WATCH 1996 4 44 4-6
12. Drug development pipeline. DRUG DEV PIPELINE 1996 1 6 1
13. DRUG DEV PIPELINE 1996 1 7 1-4
14. Genzyme Transgenics begins US phase II trial with AT-III. Genzyme Transgenics Corp PRESS RELEASE 1996 December 9
15. First transgenic goat clinical trials. SCRIP 1996 December 11 23
16. The year in the news. SCRIP MAGAZINE 1997 53 3-14
17. Genzyme Transgenics announces renewed AT-III funding from Japanese partner. Genzyme Transgenics Corp PRESS RELEASE 1997 March 26
18. Genzyme Transgenics reports record first quarter revenues. Genzyme Transgenics Corp PRESS RELEASE 1997 April 24
19. Sumitomo metal quits drug development. SCRIP 1997 2233 7
20. Genzyme Transgenics, Genzyme General establish joint venture for AT-III commercialization. Genzyme Corp PRESS RELEASE 1997 July 22
21. Genzyme Transgenics milks goats for human protein. BIOWORLD WEEK 1997 5 30 3
22. Genzyme Transgenics Corp ANNUAL REPORT 1995 December 31
23. Genzyme Transgenics begins first clinical trial of transgenic therapeutic product. Genzyme Transgenics Corp PRESS RELEASE 1996 September 5
24. Genzyme Transgenics and Genzyme Corp form partnership for transgenic AT-III development. Genzyme Transgenics Corp PRESS RELEASE 1996 April 1
25. Genzyme forms jv for antithomin III. SCRIP 1997 2255 14
26. Antithrombin deficiency in special clinical syndromes - Part II: cardiovascular surgery. Levy JH SEMIN HEMATOL 1995 32 4 Suppl 2 49-55
27. Genzyme Transgenics completes successful phase II clinical trial for recombinant human antithrombin III. Genzyme Transgenics Corp PRESS RELEASE 1997 September 4
28. Transgenic blood protein phase II successful. BIOWORLD WEEK 1997 5 37 2
29. Genzyme General posts record EPS of $.31 in third quarter. Genzyme Corp PRESS RELEASE 1997 October 23
30. Geraghty to become Genzyme Transgenics Chairman. Genzyme Transgenics Corp PRESS RELEASE 1997 November 17
31. Genzyme Transgenics, Genzyme General announce transgenic AT-III trial results. Genzyme Transgenics Corp PRESS RELEASE 1997 December 8
32. Genzyme Transgenics reports record revenues for the quarter and the year. Genzyme Transgenics Corp PRESS RELEASE 1998 March 5
33. Genzyme Transgenics Corporation completes $20 million financing. Genzyme Transgenics Corp PRESS RELEASE 1998 March 26
34. Genzyme Transgenics garners $20M. BIOWORLD WEEK 1998 6 13 4
35. Antithrombin III from transgenic goats in Japan. SCRIP 1998 2329 22
36. Genzyme Transgenics reports second quarter results. Genzyme Transgenics Corp PRESS RELEASE 1998 July 23
37. Genzyme Transgenics, Genzyme General start recombinant antithrombin III pivotal clinical trial/First transgenic therapeutic to reach phase III study Genzyme Transgenics Corp PRESS RELEASE 1998 May 13
38. Transgenically produced recombinant human AT-III enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. Levy JH, Despotis GJ, Olson P, Weisinger A, Szlam F, Meeker DP BLOOD 1997 90 Suppl1 298a-Abs 1318
39. Genzyme General ANNUAL REPORT 1997 December 31
40. Merrill Lynch: Pharmaceutical & Biotechnology Bulletin. Merrill Lynch ANALYST REPORT 1998 June 15
41. Genzyme Transgenics reports third quarter results; company announces four new strategic agreements. Genzyme Transgenics Corp PRESS RELEASE 1998 October 22
42. Genzyme Transgenics receives United States Patent for transgenic production of antithrombin III in goat's milk. Genzyme Transgenics Corp PRESS RELEASE 1998 December 1
43. Genzyme Transgenics Corporation to increase credit facility to a total of $24.6 million. Genzyme Transgenics Corp PRESS RELEASE 1998 December 22
44. Merrill Lynch: Pharmaceutical & Biotechnology Bulletin. Merrill Lynch ANALYST REPORT 1998 November 2
45. Genzyme Transgenics Corporation reports fourth quarter and year end 1998 financial results. Genzyme Transgenics Corp PRESS RELEASE 1999 March 2
46. Genzyme Transgenics Corporation announces first successful cloning of transgenic goats. Genzyme Transgenics Corp PRESS RELEASE 1999 April 26
47. Genzyme Transgenics Corp announces first successful cloning of transgenic goats. Genzyme Transgenics Corp PRESS RELEASE 1999 April 27
48. Viral Clearance, Plasma Protein Production and Prions - IBC conference, Boston, MA, USA. Bailey AC IDDB MEETING REPORT 1999 April 19-23
49. Genzyme Molecular Oncology and the ATIII LLC agree to develop aaAT-III as a potential cancer therapy. Genzyme Molecular Oncology PRESS RELEASE 1999 September 16
50. Genzyme Transgenics and Genzyme General announce phase III data on rhAT-III - first phase III trial for transgenically produced protein meets primary endpoint. Genzyme General PRESS RELEASE 2000 January 10
51. Genzyme General. HAMBRECHT & QUIST 2000 January 10-13 136
52. Chase H&Q 18th Annual Healthcare Conference San Francisco, CA, USA. Hookes J IDDB MEETING REPORT 2000 January 10-13
53. Genzyme Transgenics announces completion of public offering. Genzyme Transgenics Corp PRESS RELEASE 2000 February 10
54. Oxidation of methionine residues in antithrombin. Effects on biological activity and heparin binding. Van Patten SM, Hanson E, Bernasconi R, Zhang K, Manavalan P, Cole ES, McPherson JM, Edmunds T J BIOL CHEM 1999 274 15 10268-10276
55. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade H, McPherson JM, Cole ES BLOOD 1998 91 12 4561-4571
56. Transgenics go commercial. Young MW, Tiedemann G, Pepin RA, Turner JD, Okita WB, Harvey M, Groet S, Curling JM BIOPHARM (EUGENE, OREGON) 1998 11 7 24-28
57. Production of biopharmaceutical proteins in the milk of transgenic dairy animals. Young MW, Okita WB, Brown EM, Curling JM BIOPHARM (EUGENE, OREGON) 1997 10 6 34-38
58. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Garone L, Edmunds T, Hanson E, Bernasconi R, Huntington JA, Meagher JL, Fan B, Gettins PG BIOCHEMISTRY 1996 35 27 8881-8889
59. Transgenically produced antithrombin III. Ditullio P, Meade H, Cole ES OFFICIAL GAZETTE USPTO 1998 1217 1 479
60. Fish analysis of multiple transgene integration sites in a β-casein-antithrombin III goat line. Williams J, Ponce de Leon FA, Midura P, Harrington M, Meade H, Echelard Y THERIOGENOLOGY 1998 49 1 398
61. Tissue specific and species differences in the glycosylation pattern of antithrombin III. Edmunds T, Higgins E, Bernasconi R, Garone L, Cole ES J CELL BIOCHEM SUPPL 1994 18D 265
62. Glycosylation patterns of human proteins expressed in transgenic goat milk. Cole ES, Higgins E, Bernasconi R, Garone L, Edmunds T J CELL BIOCHEM SUPPL 1994 18D 265
63. Genzyme Transgenics reports fourth quarter and year end 1999 financial results. Genzyme Transgenics Corp PRESS RELEASE 2000 March 8
64. Genzyme General reports record fourth-quarter and 1999 financial results. Genzyme General PRESS RELEASE 2000 March 9
65. Lysine residue 114 in human antithrombin III is required for heparin pentasaccharide-mediated activation. Kridel SJ, Knauer DJ J BIOL CHEM 1997 272 7656-7660
66. Genzyme Transgenics reports first quarter 2000 financial results. Genzyme Transgenics Corp PRESS RELEASE 2000 April 19
67. Genzyme General reports strong first-quarter EPS and revenue growth. Genzyme General PRESS RELEASE 2000 April 20